| __timestamp | Mesoblast Limited | Vericel Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 54170000 | 13774000 |
| Thursday, January 1, 2015 | 65378000 | 22479000 |
| Friday, January 1, 2016 | 52263000 | 27388000 |
| Sunday, January 1, 2017 | 35072000 | 35610000 |
| Monday, January 1, 2018 | 27415000 | 49007000 |
| Tuesday, January 1, 2019 | 36983000 | 61139000 |
| Wednesday, January 1, 2020 | 50918000 | 68836000 |
| Friday, January 1, 2021 | 63586000 | 97592000 |
| Saturday, January 1, 2022 | 57967000 | 106903000 |
| Sunday, January 1, 2023 | 53107000 | 120998000 |
| Monday, January 1, 2024 | 23626000 |
In pursuit of knowledge
In the competitive world of biotechnology, operational efficiency is key. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Vericel Corporation and Mesoblast Limited from 2014 to 2023. Over this period, Vericel's SG&A expenses surged by approximately 780%, peaking in 2023. In contrast, Mesoblast's expenses fluctuated, with a notable 64% decrease from its 2015 high to 2024. This divergence highlights Vericel's aggressive expansion strategy, while Mesoblast appears to be optimizing its operational costs. The data reveals a strategic shift in the biotech landscape, where Vericel's increasing expenses may indicate a focus on growth and market penetration, whereas Mesoblast's cost-cutting could suggest a pivot towards sustainability. Missing data for Vericel in 2024 suggests a potential shift or anomaly worth monitoring.
BeiGene, Ltd. vs Vericel Corporation: SG&A Expense Trends
Neurocrine Biosciences, Inc. and Vericel Corporation: SG&A Spending Patterns Compared
Halozyme Therapeutics, Inc. vs Mesoblast Limited: SG&A Expense Trends
Breaking Down SG&A Expenses: Blueprint Medicines Corporation vs Mesoblast Limited
Selling, General, and Administrative Costs: Cytokinetics, Incorporated vs Vericel Corporation
Selling, General, and Administrative Costs: Ionis Pharmaceuticals, Inc. vs Mesoblast Limited
Rhythm Pharmaceuticals, Inc. and Vericel Corporation: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Veracyte, Inc. and Vericel Corporation
Comparing SG&A Expenses: Vericel Corporation vs Merus N.V. Trends and Insights
SG&A Efficiency Analysis: Comparing Vericel Corporation and ImmunityBio, Inc.
Cost Management Insights: SG&A Expenses for Vericel Corporation and Supernus Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Protagonist Therapeutics, Inc. and Mesoblast Limited